降糖药物对心力衰竭预后的影响  

The influences of antidiabetic medications on heart failure

作　　者：董豪坚[1] 陈纪言[1] Dong Haojian;Chen Jiyan(Department of Cardiology,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Guangzhou 510080,China)

机构地区：[1]广东省医学科学院广东省人民医院心内科,广州市510080

出　　处：《中华心力衰竭和心肌病杂志（中英文）》2020年第4期293-299,共7页Chinese Journal of Heart Failure and Cardiomyopathy

基　　金：国家十三五重点研发计划子课题(2016YFC1301202)。

摘　　要：心力衰竭(心衰)和糖尿病已经成为影响我国居民健康的重要公共卫生问题,二者常合并发生,是各自的独立危险因素。尤其2型糖尿病(T2DM),是心衰的重要危险因素之一。研究证实,心衰是T2DM患者的重要结局事件,而降糖药物治疗可能改变T2DM患者心衰发生发展的风险。因此,本文将梳理各类降糖药物对T2DM患者心衰预后影响的临床证据,重点介绍钠葡萄糖协同转运蛋白-2抑制剂(SGLT-2i)在心衰防治方面的研究进展以及在目前更新的心衰和糖尿病指南和共识中的有关推荐意见。Heart failure(HF)and diabetes mellitus(DM)have both become important public health problems affecting Chinese residents.They often occur concomitantly,and each disease independently increases the risk for the other.In particular,type 2 diabetes mellitus(T2DM)is an important risk factor of HF.Studies have confirmed that HF is a critical outcome in patients with T2DM and that glucose-lowering medications may influence the risk of HF development and progression.Thus,this paper will review the clinical evidences of the influences of various antidiabetic medications on HF in patients with T2DM with focus on the research progress of sodium and glucose cotransporter-2 inhibitor(SGLT-2i)in the prevention and treatment of HF as well as the current updated recommendations associated with SGLT-2i in guidelines and consensus of HF and DM.

关 键 词：心力衰竭 2型糖尿病 钠葡萄糖协同转运蛋白-2抑制剂 二肽基肽酶-4抑制剂 胰高血糖素样-1受体激动剂 

分 类 号：R541.6[医药卫生—心血管疾病]